Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Investment Securities (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Gains from Investment Securities data on record, last reported at $6.9 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 2.32% year-over-year to $6.9 million; the TTM value through Sep 2025 reached $6.9 million, up 2.32%, while the annual FY2024 figure was $6.7 million, 14.26% down from the prior year.
  • Gains from Investment Securities reached $6.9 million in Q3 2025 per AMPH's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $16.6 million in Q2 2023 and bottomed at -$18.3 million in Q3 2022.
  • Average Gains from Investment Securities over 5 years is $4.3 million, with a median of $5.6 million recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: tumbled 546.26% in 2022, then soared 19143.5% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $7.8 million in 2021, then increased by 1.67% to $7.9 million in 2022, then crashed by 32.22% to $5.4 million in 2023, then grew by 23.84% to $6.7 million in 2024, then increased by 4.13% to $6.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $6.9 million in Q3 2025, $1.2 million in Q2 2025, and $7.1 million in Q1 2025.